Does Wegovy cause muscle loss, and how much should you worry about it?

What STEP 1 and follow-up analyses found about lean mass

The clearest starting point is the STEP 1 trial, the pivotal 68-week study of semaglutide 2.4mg that underpins Wegovy's UK licence. Participants lost an average of around 15% of their body weight, a substantial result. Body-composition analyses from that programme found that a meaningful portion of the weight lost was lean mass, broadly in line with what researchers see during any sizeable calorie deficit, whether drug-assisted or not.

What matters is the context. In obesity research, the 25–40% lean-mass fraction is actually consistent with aggressive dietary restriction without exercise, it is not unique to semaglutide. The concern is that, because GLP-1 medicines suppress appetite so effectively, some people eat far less without necessarily eating the right things. Protein is the macronutrient most protective of muscle, and it can slip when overall intake drops sharply. The relationship between Wegovy and muscle mass is therefore as much about how people eat during treatment as about the medicine itself.

The STEP 5 extension data, looking at longer-term use, also showed that much of the lean-mass change stabilised over time rather than continuing to decline, which is reassuring for people committed to the programme. Published findings from the STEP trials are available through the STEP 1 paper in the New England Journal of Medicine.

Why semaglutide muscle loss is less alarming than headlines suggest

A common question our prescribers hear is whether the muscle lost on semaglutide will leave someone weaker or less healthy than before treatment. The short answer is: not necessarily, and usually not, when the rest of the picture is addressed.

First, the denominator matters. If someone starts treatment carrying a large amount of excess body fat, losing some lean mass alongside a much larger fat reduction still improves their ratio of fat to muscle, often substantially. Functional strength and metabolic health can improve even when the absolute lean-mass number dips slightly.

Second, the comparison group is important. People managing obesity without treatment also lose muscle during weight loss, sometimes at similar or higher rates if they rely on very low-calorie diets without support. The question is not whether semaglutide causes muscle loss compared with doing nothing; it is whether the total health picture is better with treatment, accounting for all tissues. For most people who meet the licensed criteria, the evidence says yes. If you want a fuller picture of this nuance, the detailed breakdown of whether Wegovy causes muscle loss goes through the trial data step by step.

Third, the pattern can be shifted. That is the most practically useful part of the evidence.

How to protect muscle while taking Wegovy

Two strategies have the strongest backing in the evidence. The first is protein intake. Most dietitians working in weight management recommend a target in the range of 1.2–1.6 grams of protein per kilogram of body weight per day during active weight loss, though your prescriber or a registered dietitian should give you a personalised figure. The practical challenge is that Wegovy suppresses appetite considerably, so hitting protein goals requires deliberate planning rather than eating to hunger alone. A useful habit many people find works: front-load protein at breakfast, before the day's appetite suppression peaks, rather than leaving it to the evening meal.

The second strategy is resistance exercise. Aerobic activity burns calories but does relatively little to preserve lean mass during a deficit. Two to three sessions of progressive resistance training per week (weights, resistance bands or bodyweight exercises that progressively challenge the muscles) gives the body a clear signal to retain muscle even while losing fat. The practical guide on avoiding muscle loss on Wegovy covers both of these in more detail.

It is also worth noting that the higher doses of semaglutide, including the newer 7.2mg maintenance option approved by the MHRA in early 2026, produce greater weight reduction, which means readers often ask whether you lose muscle on Wegovy at these higher doses, a question that becomes more important, not less, as doses increase. NHS guidance on weight-management injections addresses the role of wrap-around dietary and activity support precisely because of this, and you can read it on the NHS England weight-management injections page.

When to raise muscle loss with your prescriber

Most people on Wegovy do not need to stop treatment because of lean-mass concerns. But there are situations where the question deserves explicit attention. If you are over 65 (where age-related muscle decline (sarcopenia) runs alongside any treatment-related changes) or if you have a condition affecting muscle function, or if you are finding it very hard to eat enough protein because nausea is persistent, these are all worth flagging at your next clinical review.

Ongoing monitoring is part of responsible prescribing. At a regulated service like ours, every repeat supply is clinically reviewed rather than issued automatically, so there are regular touchpoints to discuss exactly this kind of thing. Questions about whether semaglutide specifically causes muscle loss differently from other GLP-1 medicines are also worth exploring with a prescriber if you are comparing options.

The cost of treatment is a fair question at this stage too. You can see how Wegovy treatment is structured and priced through our treatment options page, where the full inclusions are set out transparently.

If you want to discuss your own situation with a prescriber before starting treatment, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, not software.